Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).
Pharmacoecon Open
; 2(2): 153-163, 2018 Jun.
Article
em En
| MEDLINE
| ID: mdl-29623625
ABSTRACT
BACKGROUND:
Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders' preferences and be explicit about the trade-offs that are being made.OBJECTIVE:
The objective of this study was to use MCDA to obtain preferences and views on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to use these to assess the performance of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL).METHODS:
We used EVIDEM V3.0, an MCDA framework, and collected participants' preferences via an online survey and structured meetings.RESULTS:
Patients and clinicians expressed a preference for interventions targeting severe conditions. Payers expressed preference for treatments targeting areas with an unmet need, which are cheaper than the comparator, and with high-quality evidence. Obinutuzumab in combination with bendamustine, compared with bendamustine alone, received high positive scores for the criteria 'disease severity' and 'type of therapeutic benefit' by all three groups, and negative scores on the economic-related criteria, according to all stakeholder groups.CONCLUSIONS:
MCDA can be used to elicit the views of different stakeholder groups and has the potential to structure and inform reimbursement decisions.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
/
Qualitative_research
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article